Simplify Asset Management Inc. Acquires New Shares in DexCom, Inc. (NASDAQ:DXCM)

Simplify Asset Management Inc. acquired a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm acquired 105,405 shares of the medical device company's stock, valued at approximately $8,197,000. DexCom accounts for 0.4% of Simplify Asset Management Inc.'s investment portfolio, making the stock its 13th biggest holding.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Blue Whale Capital LLP raised its holdings in DexCom by 91.9% in the third quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company's stock valued at $15,821,000 after acquiring an additional 113,000 shares in the last quarter. Motley Fool Asset Management LLC increased its position in shares of DexCom by 168.7% in the 3rd quarter. Motley Fool Asset Management LLC now owns 272,622 shares of the medical device company's stock worth $17,993,000 after purchasing an additional 171,150 shares during the last quarter. Watts Gwilliam & Co. LLC acquired a new stake in shares of DexCom in the 4th quarter valued at about $3,334,000. Congress Asset Management Co. lifted its position in shares of DexCom by 5,456.9% during the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock worth $105,529,000 after purchasing an additional 1,332,522 shares during the last quarter. Finally, Janney Montgomery Scott LLC grew its stake in DexCom by 2,226.6% in the fourth quarter. Janney Montgomery Scott LLC now owns 232,543 shares of the medical device company's stock worth $18,085,000 after purchasing an additional 222,548 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insiders Place Their Bets

In other news, CEO Kevin R. Sayer sold 32,498 shares of the company's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $2,287,209.24. Following the transaction, the chief executive officer now directly owns 372,029 shares of the company's stock, valued at approximately $26,183,401.02. This represents a 8.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Jacob Steven Leach sold 14,076 shares of DexCom stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $990,668.88. Following the sale, the chief operating officer now directly owns 313,497 shares of the company's stock, valued at approximately $22,063,918.86. The trade was a 4.30 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 105,009 shares of company stock worth $8,044,178 in the last quarter. 0.30% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on DXCM shares. Robert W. Baird raised DexCom from a "neutral" rating to an "outperform" rating and increased their target price for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. Citigroup lifted their price objective on shares of DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a report on Tuesday, March 4th. Redburn Atlantic raised shares of DexCom from a "neutral" rating to a "buy" rating and increased their target price for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Baird R W upgraded shares of DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Finally, Canaccord Genuity Group boosted their price objective on DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a research report on Friday, February 14th. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, DexCom presently has a consensus rating of "Moderate Buy" and a consensus target price of $99.82.

DexCom Stock Down 3.7 %

Shares of DXCM stock traded down $2.66 on Thursday, reaching $69.47. 5,523,744 shares of the company's stock traded hands, compared to its average volume of 3,926,583. The business's 50 day moving average price is $82.65 and its two-hundred day moving average price is $77.02. The company has a market capitalization of $27.15 billion, a P/E ratio of 48.58, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $141.99.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, equities analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.